

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/646,807	12/05/2000 ,	Michael Wayne Graham	DAVI105.001A	1584
75	90 11/18/2002			
Frank Di Giglio			EXAMINER	
400 Garden City		SULLIVAN, DANIEL M		
Garden City, N	Y 11530		ART UNIT	PAPER NUMBER
			1636	17
			DATE MAILED: 11/18/2002	, /

Please find below and/or attached an Office communication concerning this application or proceeding.

,		Application	. No	Applicant(a)			
		Application		Applicant(s)			
	Office Action Summers	09/646,807		GRAHAM ET AL.			
Office Action Summary		Examin r		Art Unit			
		Daniel M Su		1636			
Period fo	The MAILING DATE of this communication or Reply	appears on the	cover sheet with the c	rrespondence address			
THE - External after of the control	IORTENED STATUTORY PERIOD FOR RE MAILING DATE OF THIS COMMUNICATIO ensions of time may be available under the provisions of 37 CFF SIX (6) MONTHS from the mailing date of this communication. The period for reply specified above is less than thirty (30) days, a poperiod for reply specified above, the maximum statutory per tare to reply within the set or extended period for reply will, by stareply received by the Office later than three months after the material part of the provided by the Office later than three months after the material part of the provided by the Office later than three months after the material part of the provided by the Office later than three months after the material part of the provided by the Office later than three months after the material part of the provided by the Office later than three months after the material part of the provided by the Office later than three months after the material part of the provided by the Office later than three months after the material part of the provided by the Office later than three months after the material part of the provided by the Office later than three months after the material part of the provided by the Office later than three months after the material part of the provided by the Office later than three months after the material part of the provided by the Office later than three months are provided by the Office later than three months are provided by the Office later than three months are provided by the Office later than three months are provided by the Office later than three months are provided by the Office later than three months are provided by the Office later than three months are provided by the Office later than three months are provided by the Office later than three months are provided by the Office later than three months are provided by the Office later than three months are provided by the Office later than three months are provided by the Office later than three months are provided by the Office later than three months a	N. R 1.136(a). In no even a reply within the statute fied will apply and will catute, cause the applic	t, however, may a reply be tim ory minimum of thirty (30) days expire SIX (6) MONTHS from I ation to become ABANDONEI	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).			
1)[_	Responsive to communication(s) filed on _	·					
2a)[_	This action is <b>FINAL</b> . 2b)⊠	This action is n	on-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposit	ion of Claims						
4)⊠	Claim(s) 1-40 and 43-47 is/are pending in						
	4a) Of the above claim(s) is/are without	drawn from cons	sideration.				
	Claim(s) is/are allowed.						
	6) Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
•	Claim(s) <u>1-40 and 43-47</u> are subject to rest	triction and/or el	ection requirement.				
	ion Papers						
	The specification is objected to by the Exam						
10)[	The drawing(s) filed on is/are: a) a		-				
11)	Applicant may not request that any objection to		•				
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
_		oian priority und	or 25 II S.C. \$ 110/a	) (d) or (f)			
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a,	a) All b) Some * c) None of:						
	<ul> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> </ul>						
	3. Copies of the certified copies of the p		• •				
* (	application from the International See the attached detailed Office action for a	Bureau (PCT R	Rule 17.2(a)).	· ·			
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received.  15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachmer		, , , , , , , , , , , , , , , , , , , ,	33 - 20				
2) Notice	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s	) .		(PTO-413) Paper No(s)  Patent Application (PTO-152)			

Application/Control Number: 09/646,807

Art Unit: 1636

## **DETAILED ACTION**

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-13, 17, 18, 27, 28, 34-38, 40, 43 and 47, drawn to a method of repressing, delaying or otherwise reducing expression of a target gene in an animal cell, wherein said target gene is endogenous to the animal cell.

Group II, claim(s) 1-11, 14-33, 36-39 and 41-47, drawn to a method of repressing, delaying or otherwise reducing expression of a target gene in an animal cell, wherein said target gene is derived from the genome of a pathogen.

The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I and II are united in that they both comprise the special technical feature of introduction of nucleic acid molecules comprising tandem copies of a nucleotide sequence identical to or complementary to the nucleotide sequence of a target gene. However, as evidenced by the International Search Report mailed 10 May 1999, suppression of target gene expression by introduction of nucleic acid molecules comprising tandem copies of a nucleotide sequence identical to or complementary to the nucleotide sequence of a target gene was known in the art at the time the instant application was filed. As the method of suppressing target gene expression does not represent a contribution over the prior art, the claims of Group I lack a special technical feature that is the same as or that corresponds to a special technical feature of Group II. Thus there is no special technical feature linking the recited Groups, as would be necessary to fulfill the requirement for unity of invention.

The method of Group I, being directed to suppression of endogenous genes within an animal cell, differs in both function and effect from the method of Group II, which is directed to suppression of genes comprised within the genome of a pathogenic organism. For example, the function and effect of the method of Group I could be to suppress neoplastic cell growth by inhibiting expression of an oncogene, while the function and effect of the method of Group II is limited to inhibiting expansion or toxicity of a pathogen.

Application/Control Number: 09/646,807

Art Unit: 1636

..... 4 "

Claims 2-11, 17, 18, 27, 28, 36-38, 43 and 47 embrace both Groups I and II and will therefore be examined only to the extent that they read on the elected subject matter.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Daniel M Sullivan whose telephone number is 703-305-4448. The examiner can normally be reached on Monday through Friday 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel can be reached on 703-305-1998. The fax phone numbers for the organization where this application or proceeding is assigned are 703-746-9105 for regular communications and 703-746-9105 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

dms

November 12, 2002

JAMES KETTER
PRIMARY EXAMINER